Brodalumab: short-term effectiveness and safety in real clinical practice

Int J Dermatol. 2020 Sep;59(9):e340-e341. doi: 10.1111/ijd.14866. Epub 2020 Mar 30.

Authors

Ricardo Ruiz-Villaverde¹, Manuel Galán-Gutierrez², Jose Carlos Armario-Hita³, Jose Carlos Ruiz-Carrascosa¹, Pilar Font-Ugalde⁴

Affiliations

¹ Dermatology Unit, Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria ibs, Granada, Spain.
² Dermatology Unit, Hospital Universitario Reina Sofia, IMIBIC, Universidad de Córdoba, Córdoba, Spain.
³ Dermatology Unit, Hospital Universitario Puerto Real, Cádiz, Spain.
⁴ Hospital Universitario Reina Sofía de Córdoba, IMIBIC, Universidad de Córdoba (UCO), Córdoba, Spain.

PMID: 32227476
DOI: 10.1111/ijd.14866

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized*
Humans
Psoriasis* / drug therapy
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
brodalumab